Table of Content 1. 2021, a year to forget for the sector, or to learn from? 2. Status on COVID-19 3. Key Events in 2021 (Morphosys transformative deal, main approvals, Galapagos, Oncopeptides) 4. 2021 Highlights (Approval rates, IPOs & new listings, financing) 5. 2021 Lowlights (Clinical trial success rates, performances of commercial launches, Sweden, deals)[…]
Table of Content 1. Intro on COVID-19 2. How the European listed biotech companies try to help for vaccines and therapies against COVID-19 3. 2020 Highlights (financing, Genmab, Morphosys, approvals, “Billion Euro Biotech Club”, valuations) 4. 2020 Lowlights (Galapagos, Genfit, DBV, IPOs, AIM) 5. 2020 Deals and M&As 6. 2020 Stock and Index Performances 7.[…]
2018 was a very bad year for the European biotech landscape, so the question was whether a rebound could take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]
This is the fifth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2, Part 3 or Part 4. The full report is now available here. Part 5 – Table of Content 7. Deals 8. Portrait of a “typical” biotech company listed in Europe 9. Conclusion 2018[…]
This is the fourth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2 or Part 3. The full report is now available here. Part 4 – Table of Content 5. Financing 6. Other financial metrics: cash burn, extra cash sources, cash balance, profits & losses 6.1[…]
This is the third part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, or Part 2. The full report is now available here. Part 3 – Table of Content 3. Market data 3.1 Market capitalization 3.2 Stock performances 3.3 Market Liquidity 4. Employment References 3. Market data 3.1[…]
This is the second part of our 2018 review dedicated to the European public biotech landscape. Check out the introduction and first part here. The full report is now available here. Part 2 – Table of Content 2. R&D Pipeline & Commercial Products 2.1 Unique product candidates in active clinical development, indications and therapeutic areas[…]
This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data at the European level[…]